An observational study in Vestibular Schwannoma, sponsored by Haukeland University Hospital. Active, not recruiting at 1 site in Norway. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Haukeland University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Previous studies have shown that vertigo is the symptoms that mostly affect quality of life in patients with vestibular schwannoma. There is still limited knowledge as to why some patients with this disorder develop vertigo, while others with the same diagnosis do not. The purpose of this study is to measure symptom-related quality of life and to relate this to objective disease characteristics at baseline.
This is a longitudinal observational study with data collected at baseline and after treatment.
Variables collected at baseline include age, sex, tumor size, location, type (cystic/solid), tumor side, symptom variables including Dizziness Handicap Inventory, Vertigo Symptom Scale Short Form, Haukeland Dizziness Questionnaire, Visual analog scale, Hospital Anxiety and Depression Scale, RAND-12, dynamic posturography, video-based head impulse test, bithermal caloric tests, ocular and cervical vestibular evoked myogenic potentials.
Follow-up data after 1 year are the same patient-reported outcomes as at baseline.
100 studies on the registry are indexed under Neuroma, Acoustic; 28 are open to participants now.
This study's enrollment of 155 is above the median of 61 across 26 observational studies indexed under Neuroma, Acoustic.
Browse Neuroma, Acoustic studies →Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients in Norway with newly diagnosed vestibular schwannoma (VS) are referred to Haukeland University Hospital for evaluation. The size of the study population therefore depends on the incidence of VS in Norway and the inclusion period. The incidence of VS in Norway is approximately 150 per year in a population of 5.2 million.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dizziness Handicap Inventory (DHI)
25-item symptom score 0 - 100 points on dizziness handicap severity
Time frame: Baseline and 1-year follow-up
Vertigo Symptom Scale Short Form
15-item symptom score 0 - 60 points on vertigo symptom quality
Time frame: Baseline and 1-year follow-up
Haukeland Dizziness Questionnaire (HDQ-10)
10-item symptom score 0 - 30 points on vertigo symptom severity
Time frame: Baseline and 1-year follow-up
Vertigo Visual Analog Scale
100 mm visual analog scale on vertigo symptom severity
Time frame: Baseline and 1-year follow-up
Hospital Anxiety and Depression Scale (HADS)
14-item anxiety and depression score 0 - 42 points
Time frame: Baseline and 1-year follow-up
RAND-12
12-item health-related quality of life score
Time frame: Baseline and 1-year follow-up
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2017 to primary completion in Jun 2019, 26 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital →